Biogen Q1 Results Top Estimates; Reaffirms FY23 Outlook
(RTTNews) - Biotechnology company Biogen Inc. (BIIB) reported Tuesday net income attributable to the company for the first quarter of $387.9 million or $2.67 per share, higher than $303.8 million or $2.06 per share in the prior-year quarter.
Excluding items, adjusted earnings for the quarter were $3.40 per share, compared to $3.62 per share in the year-ago quarter.
On average, 24 analysts polled by Thomson Reuters expected the company to report earnings of $3.28 per share for the quarter. Analysts' estimates typically exclude special items.
Total revenue for the quarter declined 2.7 percent to $2.46 billion from $2.53 billion in the same quarter last year. Revenues were down 0.4 percent in constant currency. Analysts expected revenues of $2.34 billion for the quarter.
Looking ahead to fiscal 2023, the company continues to project adjusted earnings in a range of $15.00 to $16.00 per share on a revenue decline in the mid-single digits.
The Street is looking for earnings of $15.48 per share on a revenue decline of 6.0 percent to $9.56 billion for the year.
For more earnings news, earnings calendar, and earnings for stocks, visit rttnews.com
Biogen Q2 Results Top Estimates; Boosts FY24 Outlook
Biogen Says European Commission Grants TOFIDENCE Biosimilar Approval For Multiple Indications
Biogen To Buy Human Immunology Biosciences In Deal Valued At Up To $1.8 Bln
Biogen Q1 Adj. EPS Tops Estimates, But Sales Miss; Reaffirms FY24 Outlook
Biogen Says European Commission Revokes Marketing Authorizations For Generic Versions Of TECFIDERA
Biogen Q2 Results Top Estimates; Backs FY23 Outlook
Biogen Q4 Results Top Estimates
